E088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.337
Abstract: Guselkumab is a monoclonal antibody approved to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). In this analysis, safety data from 11 Phase 2/3 studies of guselkumab were pooled to evaluate guselkumab safety in… read more here.
Keywords: scientific affairs; johnson johnson; johnson; janssen scientific ... See more keywords
SAT0175 A descriptive analysis of real-world treatment patterns in a turkish rheumatology population that continued innovator infliximab (REMICADE) therapy or switched to biosimilar infliximab
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1128
Abstract: Objectives This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or continued on IFX following availability of CT-P13 in the Turkish… read more here.
Keywords: infliximab; affairs llc; janssen scientific; scientific affairs ... See more keywords
Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1287-p
Abstract: This study compared HbA1c control, treatment patterns, and costs in adults with T2DM initiated on CANA or a GLP-1 based on administrative claims data from the HealthCore Integrated Research Database (4/2013-02/2016) augmented with laboratory data.… read more here.
Keywords: treatment; affairs llc; self janssen; janssen scientific ... See more keywords
1517-P: Characteristics and Burden of Macro, Micro, and Normoalbuminuria in Patients with Type 2 Diabetes (T2D)
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1517-p
Abstract: Individuals with T2D and diabetic nephropathy are at higher risk for adverse cardiovascular events. This study compared patient characteristics and disease burden by severity of albuminuria (normoalbuminuria [NOR], microalbuminuria [MIU], macroalbuminuria [MAU]) among T2D patients… read more here.
Keywords: affairs llc; self janssen; janssen scientific; scientific affairs ... See more keywords